scholarly journals AYUSH- 64: A Potential Therapeutic Agent in COVID-19

2022 ◽  
pp. 100538
Author(s):  
Ashok Kumar Panda ◽  
Sarbeswar Kar ◽  
Amit Kumar Rai ◽  
B.C.S. Rao ◽  
N. Srikanth
Keyword(s):  
Therapeutic Agent ◽  
Potential Therapeutic Agent

Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma

2020 ◽  
Vol 26 (36) ◽  
pp. 4675-4684 ◽  
Author(s):  
Shabierjiang Jiapaer ◽  
Takuya Furuta ◽  
Yu Dong ◽  
Tomohiro Kitabayashi ◽  
Hemragul Sabit ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Screening ◽  
Therapeutic Agent ◽  
Gelatin Zymography ◽  
Therapeutic Agents ◽  
Drug Candidate ◽  
Potential Therapeutic Agent ◽  
Sphere Formation ◽  
Improve Patient

Background: Glioblastomas (GBMs) are aggressive malignant brain tumors. Although chemotherapy with temozolomide (TMZ) can extend patient survival, most patients eventually demonstrate resistance. Therefore, novel therapeutic agents that overcome TMZ chemoresistance are required to improve patient outcomes. Purpose: Drug screening is an efficient method to find new therapeutic agents from existing drugs. In this study, we explored a novel anti-glioma agent by drug screening and analyzed its function with respect to GBM treatment for future clinical applications. Methods: Drug libraries containing 1,301 diverse chemical compounds were screened against two glioma stem cell (GSC) lines for drug candidate selection. The effect of selected agents on GSCs and glioma was estimated through viability, proliferation, sphere formation, and invasion assays. Combination therapy was performed to assess its ability to enhance TMZ cytotoxicity against GBM. To clarify the mechanism of action, we performed methylation-specific polymerase chain reaction, gelatin zymography, and western blot analysis. Results: The acyl-CoA synthetase inhibitor 2-fluoropalmitic acid (2-FPA) was selected as a candidate anti-glioma agent. 2-FPA suppressed the viability and stem-like phenotype of GSCs. It also inhibited proliferation and invasion of glioma cell lines. Combination therapy of 2-FPA with TMZ synergistically enhanced the efficacy of TMZ. 2-FPA suppressed the expression of phosphor-ERK, CD133, and SOX-2; reduced MMP-2 activity; and increased methylation of the MGMT promoter. Conclusion: 2-FPA was identified as a potential therapeutic agent against GBM. To extend these findings, physiological studies are required to examine the efficacy of 2-FPA against GBM in vivo.

Ibuprofen and Glutathione Conjugate as a Potential Therapeutic Agent for Treating Alzheimer's Disease

2010 ◽  
Vol 344 (3) ◽  
pp. 139-148 ◽  
Author(s):  
Francesco Pinnen ◽  
Piera Sozio ◽  
Ivana Cacciatore ◽  
Catia Cornacchia ◽  
Adriano Mollica ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agent ◽  
Glutathione Conjugate ◽  
Potential Therapeutic Agent

Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis

2014 ◽  
Vol 90 (1) ◽  
pp. 50-61 ◽  
Author(s):  
Jing Jin ◽  
Jinping Hu ◽  
Wanqi Zhou ◽  
Xiaojian Wang ◽  
Qiong Xiao ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Therapeutic Agent ◽  
Autoimmune Encephalitis ◽  
S1p1 Receptor ◽  
Potential Therapeutic Agent
Sign in / Sign up

Export Citation Format

Share Document